Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Cacciapaglia

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Autoimmunity Reviews|November 13, 2023
Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohortFabiola Atzeni, Fabio Cacciapaglia, James Galloways, et al.
Internal and Emergency Medicine|November 11, 2025
Sjögren's disease and concomitant fibromyalgia: clinical profile and implications for disease activity assessmentStefano Stano, Vincenzo Venerito, Daniele Domanico, et al.
Internal and Emergency Medicine|May 22, 2026
The systemic immune-inflammation biomarkers in Sjögren's disease: associations with disease activity and extraglandular manifestations in a multicentric Italian cohortStefano Stano, Venerito Vincenzo, Maria Giannotta, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective surveyGiuseppe Lopalco, Vincenzo Venerito, Luca Cantarini, et al.
Journal of Translational Autoimmunity|September 19, 2022
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapiesLaura Gragnani, Marcella Visentini, Serena Lorini, et al.
Autoimmunity Reviews|November 4, 2008
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study)Barbara Maria Colombo, Fabio Cacciapaglia, Matteo Puntoni, et al.
Clinical and Experimental Rheumatology|December 16, 2016
Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE)Fulvia Ceccarelli, Umberto Massafra, Carlo Perricone, et al.
Rheumatology (Oxford, England)|September 8, 2022
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patientsFabio Cacciapaglia, Paolo Airò, Marco Fornaro, et al.
European Journal of Internal Medicine|August 15, 2024
Towards a comprehensive approach to the management and prognosis of systemic sclerosis's patients: The role of comorbidities in the SPRING-SIR registryMartina Orlandi, Silvia Bellando-Randone, Rossella De Angelis, et al.
Seminars in Arthritis and Rheumatism|February 21, 2017
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritisFlorenzo Iannone, Leonardo Santo, Maria Grazia Anelli, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Autoimmunity Reviews|November 13, 2023
Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohortFabiola Atzeni, Fabio Cacciapaglia, James Galloways, et al.
Internal and Emergency Medicine|November 11, 2025
Sjögren's disease and concomitant fibromyalgia: clinical profile and implications for disease activity assessmentStefano Stano, Vincenzo Venerito, Daniele Domanico, et al.
Internal and Emergency Medicine|May 22, 2026
The systemic immune-inflammation biomarkers in Sjögren's disease: associations with disease activity and extraglandular manifestations in a multicentric Italian cohortStefano Stano, Venerito Vincenzo, Maria Giannotta, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective surveyGiuseppe Lopalco, Vincenzo Venerito, Luca Cantarini, et al.
Journal of Translational Autoimmunity|September 19, 2022
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapiesLaura Gragnani, Marcella Visentini, Serena Lorini, et al.
Autoimmunity Reviews|November 4, 2008
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study)Barbara Maria Colombo, Fabio Cacciapaglia, Matteo Puntoni, et al.
Clinical and Experimental Rheumatology|December 16, 2016
Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE)Fulvia Ceccarelli, Umberto Massafra, Carlo Perricone, et al.
Rheumatology (Oxford, England)|September 8, 2022
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patientsFabio Cacciapaglia, Paolo Airò, Marco Fornaro, et al.
European Journal of Internal Medicine|August 15, 2024
Towards a comprehensive approach to the management and prognosis of systemic sclerosis's patients: The role of comorbidities in the SPRING-SIR registryMartina Orlandi, Silvia Bellando-Randone, Rossella De Angelis, et al.
Seminars in Arthritis and Rheumatism|February 21, 2017
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritisFlorenzo Iannone, Leonardo Santo, Maria Grazia Anelli, et al.
Pageof 12